Sensitivity to the abl inhibitor STI571 in fresh leukaemic cells obtained from chronic myelogenous leukaemia patients in different stages of disease

British Journal of Haematology

Volumn 112, Issue 4, 2001, Pages 972-974

  Gambacorti Passerini, Carlo ^a,b   Barni, Rossella ^a   Marchesi, Edoardo ^a   Verga, Magda ^a   Rossi, Francesca ^a   Rossi, Fabio ^a   Pioltelli, Pietro ^a   Pogliani, Enrico ^a   Corneo, Gian Marco ^a  

^a SAN GERARDO HOSPITAL   (Italy)

^b NATIONAL CANCER INSTITUTE   (Italy)

Author keywords

BCR ABL; Leukaemia; Resistance; STI571; Therapy

Indexed keywords

IMATINIB;

ADULT; AGED; ARTICLE; BLAST CELL CRISIS; CANCER STAGING; CHRONIC DISEASE; CHRONIC MYELOID LEUKEMIA; CLINICAL ARTICLE; CONTROLLED STUDY; DRUG SENSITIVITY; HUMAN; HUMAN CELL; LEUKEMIA CELL; PRIORITY JOURNAL;

ADULT; AGED; BLAST CRISIS; FUSION PROTEINS, BCR-ABL; HUMANS; LEUKEMIA, MYELOID, CHRONIC; MIDDLE AGED; PIPERAZINES; PYRIMIDINES; TUMOR CELLS, CULTURED;

EID: 0035051044     PISSN: 00071048     EISSN: None     Source Type: Journal    
DOI: 10.1046/j.1365-2141.2001.02653.x     Document Type: Article

References (9)

1. The tyrosine kinase inhibitor CGP57148B selectively inhibits the growth of BCR-ABL-positive cells
2. Effects of a selective inhibitor of the Abl tyrosine kinase on the growth of Bcr-Abl positive cells
3. Activity of an ABL specific tyrosine kinase inhibitor in patients with BCR-ABL positive acute leukemias, including chronic myelogenous leukemia in blast crisis
4. Clinical efficacy and safety of an ABL specific tyrosine kinase inhibitor as targeted therapy for chronic myelogenous leukemia
5. Inhibition of the ABL kinase activity blocks the proliferation of BCR/ABL+ leukemic cells and induces apoptosis
6. + leukemic cells to the Abl inhibitor STI571
7. In vivo eradication of human BCR/ABL-positive leukemia cells with an ABL kinase inhibitor
8. Induction of resistance to the Abelson inhibitor STI571 in human leukemic cells through gene amplification
9. A BCR/ABL kinase antagonist for chronic myelogenous leukemia: A promising path for progress emerges